Valuation: Waverley Pharma Inc.

Market Cap 1.08M 758K 687K 635K 573K 71.45M 1.12M 7.63M 3.03M 38.17M 2.84M 2.78M 121M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.48M 3.14M 2.85M 2.63M 2.38M 296M 4.64M 31.65M 12.55M 158M 11.8M 11.54M 503M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day+100.00%
Current month+100.00%
1 month+100.00%
3 months+33.33%
6 months+100.00%
1 month 0.02
Extreme 0.02
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.1
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 31/01/2020
Director of Finance/CFO - 31/12/2019
Director TitleAgeSince
Chairman 79 13/12/2016
Director/Board Member 54 13/12/2016
Director/Board Member - 21/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/08/26 Option

Chairman

-10,000,000 18.5185%
24/06/24 Other

Director

0 0.0000%
18/08/21 Other

Chairman

0 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%0.00%0.00%-42.86% 758K
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average +9.45%+0.04%+33.99%+165.49% 41B
Weighted average by Cap. -0.83%+0.20%+37.23%+162.19%

Financials

2024 2025
Net sales 475K 334K 302K 280K 252K 31.45M 492K 3.36M 1.33M 16.8M 1.25M 1.23M 53.33M 1.35M 947K 858K 794K 716K 89.29M 1.4M 9.53M 3.78M 47.7M 3.55M 3.48M 151M
Net income -947K -665K -602K -557K -503K -62.66M -980K -6.69M -2.65M -33.47M -2.49M -2.44M -106M -499K -350K -317K -294K -265K -33.03M -517K -3.53M -1.4M -17.64M -1.31M -1.29M -56M
Net Debt 2.83M 1.99M 1.8M 1.66M 1.5M 187M 2.93M 20M 7.93M 100M 7.45M 7.3M 318M 3.4M 2.39M 2.16M 2M 1.8M 225M 3.52M 24.02M 9.52M 120M 8.95M 8.76M 381M
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock